Estrogen Receptor Modulators
"Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that possess antiestrogenic actions but can also produce estrogenic effects as well. They act as complete or partial agonist or as antagonist. They can be either steroidal or nonsteroidal in structure.
| Descriptor ID |
D020847
|
| MeSH Number(s) |
D06.347.360 D27.505.696.399.450.360
|
| Concept/Terms |
Estrogen Receptor Modulators- Estrogen Receptor Modulators
- Modulators, Estrogen Receptor
- Receptor Modulators, Estrogen
- Antiestrogens
- Antiestrogen
- Estrogen Receptor Modulator
- Modulator, Estrogen Receptor
- Receptor Modulator, Estrogen
|
Below are MeSH descriptors whose meaning is more general than "Estrogen Receptor Modulators".
Below are MeSH descriptors whose meaning is more specific than "Estrogen Receptor Modulators".
This graph shows the total number of publications written about "Estrogen Receptor Modulators" by people in this website by year, and whether "Estrogen Receptor Modulators" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 0 | 1 |
| 2003 | 1 | 0 | 1 |
| 2006 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Estrogen Receptor Modulators" by people in Profiles.
-
Upregulation of the EGFR/MEK1/MAPK1/2 signaling axis as a mechanism of resistance to antiestrogen-induced BimEL dependent apoptosis in ER+ breast cancer cells. Int J Oncol. 2023 Feb; 62(2).
-
Bortezomib blocks the catabolic process of autophagy via a cathepsin-dependent mechanism, affects endoplasmic reticulum stress and induces caspase-dependent cell death in antiestrogen-sensitive and resistant ER+ breast cancer cells. Autophagy. 2010 Jan; 6(1):19-35.
-
Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the Women's Environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst. 2008 Jan 02; 100(1):32-40.
-
Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res. 2006 Dec 15; 66(24):11954-66.
-
Value of the micropig model of menopause in the assessment of benefits and risks of postmenopausal therapies for cardiovascular and reproductive tissues. Fertil Steril. 2003 Mar; 79 Suppl 1:779-88.
-
Tamoxifen inhibits angiogenesis in estrogen receptor-negative animal models. Clin Cancer Res. 2000 Nov; 6(11):4359-64.